Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 / 抑制剂/激动剂 / 神经信号通路 / 葡萄糖神经酰胺合成酶 / Eliglustat

依利格鲁司特 /Eliglustat {[allProObj[0].p_purity_real_show]}

货号：A848004 同义名： Genz 99067;GENZ-112638

Eliglustat is a specific and potent inhibitor of glucosylceramide synthase.

Eliglustat 化学结构 CAS号：491833-29-5
Eliglustat 化学结构
CAS号：491833-29-5
Eliglustat 3D分子结构
CAS号：491833-29-5
Eliglustat 化学结构 CAS号：491833-29-5
Eliglustat 3D分子结构 CAS号：491833-29-5
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Eliglustat 纯度/质量文件 产品仅供科研

货号：A848004 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
• JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
• BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
• J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
• PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >

Eliglustat 生物活性

描述 Eliglustat is a selective inhibitor of glucosylceramide synthase that is extensively metabolized by CYP2D6 and, to a lesser extent by CYP3A4; it is also an inhibitor of the P-gp transporter[3]. Eliglustat is an oral inhibitor of glucosylceramide synthase which is used in the therapy of type 1 Gaucher disease[4]. Eliglustat inhibits glucosylceramide synthase, thereby decreasing production of the substrate glucosylceramide and reducing its accumulation[5]. Administration of eliglustat to Swiss CD-1 mice at 0, 10, 25 or 75 mg/kg/day for 104 weeks by dietary admixture did not influence survival or bodyweight evolution, or produce any clinical indication of poor condition. Eliglustat was not carcinogenic to mice or rats in standard lifetime bioassays[6].

Eliglustat 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01074944 Gaucher Disease Phase 3 Completed - -
NCT00358150 Gaucher Disease, Type 1 ... 展开 >> Cerebroside Lipidosis Syndrome Glucocerebrosidase Deficiency Disease Glucosylceramide Beta-Glucosidase Deficiency Disease Gaucher Disease, Non-Neuronopathic Form 收起 << Phase 2 Completed - United States, New York ... 展开 >> New York University New York, New York, United States New York, New York, United States Argentina Aprillus Asistencia e Investigación Buenos Aires, Argentina Hospital de Oncologia Maria Curie Buenos Aires, Argentina IMAI Buenos Aires, Argentina Instituto Argentino de Diagnostico y Tratamiento (IADT) Buenos Aires, Argentina Buenos Aires, Argentina Hospital Ramos Mejia Ciudad Autonoma de Buenos Aires, Argentina Israel Rambam Medical Center Haifa, Israel Haifa, Israel Sha'are Zedek Medical Centre Jerusalem, Israel Jerusalem, Israel Italy Universita degli Studi di Milano Milano, Italy Mexico Instituto Mexicano del Seguro Social D.f., Mexico Mexico City, Mexico Russian Federation Hematology Research Center of Ministry of Healthcare of the Russian Federation Moscow, Russian Federation Moscow, Russian Federation 收起 <<
NCT00943111 - Completed - -

Eliglustat 参考文献

[1]Shayman JA. ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease. Drugs Future. 2010 Aug 1;35(8):613-620.

[2]Yew NS, Zhao H, et al. Increased hepatic insulin action in diet-induced obese mice following inhibition of glucosylceramide synthase. PLoS One. 2010 Jun 21;5(6):e11239.

[3]Almeida-Calpe A, López de Frutos L, Medrano-Engay B, García-García CB, Ribate MP, Giraldo P. Metabolizing profile of the cytochrome pathway CYP2D6, CYP3A4 and the ABCB 1 transporter in Spanish patients affected by Gaucher disease. Chem Biol Interact. 2021 Aug 25;345:109527

[4]LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Eliglustat. 2018 Mar 5

[5]Balwani M, Burrow TA, Charrow J, Goker-Alpan O, Kaplan P, Kishnani PS, Mistry P, Ruskin J, Weinreb N. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. Mol Genet Metab. 2016 Feb;117(2):95-103

[6]Dagher R, Watzinger M, Chevalier G, Thirion-Delalande C, Gervais F, Forster R. Carcinogenicity testing of eliglustat in mice and rats. Regul Toxicol Pharmacol. 2015 Oct;73(1):401-12

Eliglustat 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.47mL

0.49mL

0.25mL

12.36mL

2.47mL

1.24mL

24.72mL

4.94mL

2.47mL

Eliglustat 技术信息

CAS号491833-29-5
分子式C23H36N2O4
分子量 404.543
别名 Genz 99067;GENZ-112638
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,2-8°C
溶解度

DMSO: 105 mg/mL(259.55 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方

Tags: Eliglustat | 491833-29-5 | Genz 99067 | Genz99067 | Genz-99067 | Glucocerebroside Synthase Inhibitor | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Eliglustat 纯度/质量文件 | Eliglustat 生物活性 | Eliglustat 临床数据 | Eliglustat 参考文献 | Eliglustat 实验方案 | Eliglustat 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z